Search results
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 14 hours agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 7 hours agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 10 hours agoPfizer disclosed on May 7 that a child participating in another...
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 14 hours agogained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 1 day agoDespite a bevy of promising updates for its cancer treatments, Pfizer stock remains trapped below a...
Pfizer, Flagship to focus on obesity drugs under $100M collaboration - Boston Business Journal
The Business Journals· 1 day agoAlmost a year after Cambridge’s Flagship Pioneering and Pfizer Inc. announced a partnership to...
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors
Zacks via Yahoo Finance· 1 day agoPfizer (PFE) closed the latest trading day at $27.66, indicating a -1.32% change from the previous...
Pfizer gene therapy for Duchenne fails to meet goals of key trial
BioPharma Dive via Yahoo Finance· 1 day agoThe negative results from the Phase 3 study, called Ciffreo, come a little more than a month after ...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 16 hours agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Pfizer faces setback with gene therapy acquired from North Carolina firm - Triangle Business Journal
The Business Journals· 8 hours agoPfizer is facing a major clinical setback in a gene therapy program with ties to the Triangle. The...